<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04398095</url>
  </required_header>
  <id_info>
    <org_study_id>HOT1</org_study_id>
    <nct_id>NCT04398095</nct_id>
  </id_info>
  <brief_title>Radiotherapy With Hyperthermia in Recurrent and Radiation-Induced Sarcomas</brief_title>
  <acronym>HOT</acronym>
  <official_title>Hyperthermia and Radiotherapy in the Treatment for In-field Recurrent and Radiation-induced Soft Tissue and Bone Sarcomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maria Sklodowska-Curie Institute - Oncology Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Maria Sklodowska-Curie Institute - Oncology Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      After a screening, which consists of biopsy, physical examination, initial diffusion-weighted
      magnetic resonance imaging (DWI-MRI) or body computed tomography (CT) scan, blood tests and
      case analysis on Multidisciplinary Team (MDT) meeting, a patient with radiation-induced or
      in-field recurrent sarcoma will receive the hypofractionated radiotherapy with deep
      hyperthermia (twice a week) within three weeks. The response analysis in CT or DWI-MRI and
      toxicity assessment will be performed after 6 weeks. In resectable tumors, a patient will be
      referred to surgery. In the case of unresectability, the patient will followed-up.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Due to the rarity of radiation-induced (RIS) or previously irradiated recurrent (PIRS)
      sarcomas, no guidelines nor randomized prospective clinical trials on this topic exist. Thus
      the management of RIS and PIR is challenging. The only curable modality in non-metastatic
      RIS/PIRS is radical resection with wide negative margins. The role of secondary radiotherapy
      in locally advanced RIS/PIRS is unclear, mostly due to the concerns about possible severe
      side effects after re-irradiation.

      The addition of deep hyperthermia to irradiation and in the prolonged gap between the end of
      moderately hypofractionated radiotherapy (with or without integrated boost) and surgery may
      allow obtaining the long-term local control with the maintenance of a good treatment
      tolerance Hyperthermia is a method of increasing the temperature in the tumor to damage
      cancer cells with minimum injury to the normal cells. It should be combined with another
      treatment modality (radio- or chemotherapy) rather than used alone. Its efficacy was proven
      in clinical trials. Treatment tolerance is usually very good.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 23, 2019</start_date>
  <completion_date type="Anticipated">April 2023</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ratio of late adverse events</measure>
    <time_frame>18 months</time_frame>
    <description>Ratio of grade 3 or higher late adverse events related to reirradiation, according to CTCAE 5.0</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Local control rate</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cancer-specific survival</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Radiation Induced Neoplasms</condition>
  <condition>Radiation-Induced Cancer</condition>
  <condition>Recurrent Sarcoma</condition>
  <condition>Recurrent Soft Tissue Sarcoma</condition>
  <arm_group>
    <arm_group_label>Radiotherapy with hyperthermia in resectable sarcomas</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>12x 3 Gy (4 fractions per week) + hyperthermia (6x) + surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Radiotherapy with hyperthermia in non-resectable sarcomas</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>12x 3 Gy with simultaneous integrated boost 3.5 Gy (4 fractions per week) + hyperthermia (6x)</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Hypofractionated radiotherapy</intervention_name>
    <description>Resectable tumors: preoperative hypofractionated 12x 3 Gy radiotherapy (4 days in a week, three weeks) prescribed on planned target volume (tumor volume + elective margins + setup/error margin) with daily image guidance with cone beam-CT or kV-portal position verification.
Non-resectable tumors: definitive hypofractionated 12x 3 Gy radiotherapy prescribed on planned target volume (tumor volume + elective margins + setup/error margin) with simultaneous integrated boost 3.5 Gy per fraction prescribed on boost planned target volume (tumor volume + setup/error margin), 4 days in a week, three weeks.
Radiotherapy with daily image guidance with cone beam-CT or kV-portal position verification.</description>
    <arm_group_label>Radiotherapy with hyperthermia in non-resectable sarcomas</arm_group_label>
    <arm_group_label>Radiotherapy with hyperthermia in resectable sarcomas</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Hyperthermia</intervention_name>
    <description>Deep hyperthermia (Celsius TCS or BSD-2000) according to local protocol combined with radiotherapy, twice a week.</description>
    <arm_group_label>Radiotherapy with hyperthermia in non-resectable sarcomas</arm_group_label>
    <arm_group_label>Radiotherapy with hyperthermia in resectable sarcomas</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Able to provide informed consent

          -  Eastern Cooperative Oncology Group performance status 0 - 2

          -  Age ≥18 years old

          -  Histologically-proven diagnosis of radiation-induced or recurrent soft tissue sarcoma

          -  Previous radiotherapy within the planned target volume

        Exclusion Criteria:

          -  Histologic diagnosis of rhabdomyosarcoma (except spindle cell and pleomorphic
             subtype), osteogenic sarcoma, Ewing's sarcoma/PNET, aggressive fibromatosis

          -  Contraindications to radiotherapy or hyperthermia

          -  Predicted unacceptable high risk of reirradiation-related toxicity, in the
             Investigator's judgment

          -  Unresectable metastases
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mateusz J Spałek, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Maria Sklodowska-Curie National Research Institute of Oncology in Warsaw</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mateusz J Spałek, MD PhD</last_name>
    <phone>+48225462455</phone>
    <email>mateusz.spalek@pib-nio.pl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Aneta Borkowska, MD</last_name>
    <phone>+48225462455</phone>
    <email>aneta.borkowska@pib-nio.pl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The Maria Sklodowska-Curie National Research Institute of Oncology in Warsaw</name>
      <address>
        <city>Warsaw</city>
        <state>Mazovian</state>
        <zip>02-781</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mateusz J Spałek, MD PhD</last_name>
      <phone>+48225462455</phone>
      <email>mateusz.spalek@pib-nio.pl</email>
    </contact>
    <investigator>
      <last_name>Aneta Borkowska, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mateusz J Spałek, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Piotr Ł Rutkowski, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <reference>
    <citation>de Jong MA, Oldenborg S, Bing Oei S, Griesdoorn V, Kolff MW, Koning CC, van Tienhoven G. Reirradiation and hyperthermia for radiation-associated sarcoma. Cancer. 2012 Jan 1;118(1):180-7. doi: 10.1002/cncr.26252. Epub 2011 Jun 28.</citation>
    <PMID>21713762</PMID>
  </reference>
  <reference>
    <citation>Haas RL, Miah AB, LePechoux C, DeLaney TF, Baldini EH, Alektiar K, O'Sullivan B. Preoperative radiotherapy for extremity soft tissue sarcoma; past, present and future perspectives on dose fractionation regimens and combined modality strategies. Radiother Oncol. 2016 Apr;119(1):14-21. doi: 10.1016/j.radonc.2015.12.002. Epub 2015 Dec 21. Review.</citation>
    <PMID>26718153</PMID>
  </reference>
  <reference>
    <citation>Koseła-Paterczyk H, Szacht M, Morysiński T, Ługowska I, Dziewirski W, Falkowski S, Zdzienicki M, Pieńkowski A, Szamotulska K, Switaj T, Rutkowski P. Preoperative hypofractionated radiotherapy in the treatment of localized soft tissue sarcomas. Eur J Surg Oncol. 2014 Dec;40(12):1641-7. doi: 10.1016/j.ejso.2014.05.016. Epub 2014 Sep 20.</citation>
    <PMID>25282099</PMID>
  </reference>
  <reference>
    <citation>Lindner LH, Issels RD. Hyperthermia in soft tissue sarcoma. Curr Treat Options Oncol. 2011 Mar;12(1):12-20. doi: 10.1007/s11864-011-0144-6. Review.</citation>
    <PMID>21360087</PMID>
  </reference>
  <reference>
    <citation>Borghede G, Hedelin H. Radiotherapy of localised prostate cancer. Analysis of late treatment complications. A prospective study. Radiother Oncol. 1997 May;43(2):139-46.</citation>
    <PMID>9192958</PMID>
  </reference>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 18, 2020</study_first_submitted>
  <study_first_submitted_qc>May 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 21, 2020</study_first_posted>
  <last_update_submitted>May 21, 2020</last_update_submitted>
  <last_update_submitted_qc>May 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
    <mesh_term>Neoplasms, Radiation-Induced</mesh_term>
    <mesh_term>Fever</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

